Development asset linked to Immedica Pharma AB in public FDA and regional records.
pharma · Arginase 1 deficiency (ARG1-D)
Immedica Pharma AB
Immedica Pharma AB drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Stockholm, SE HQ
2018 Founded
179 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Stockholm, SE
- Founded
- 2018
- Employees
- 179
- Programs
- 1
- Drugs
- 4
- Patents
- 0
Immedica Pharma AB pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Immedica Pharma AB drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Immedica Pharma AB in public FDA and regional records.
-
pegzilarginase
Alimentary tract and metabolism (A16)Alimentary tract and metabolism (A16) compound in Immedica Pharma AB's portfolio. Molecular target: L-arginine.
- Target
- L-arginine
- Mechanism
- L-arginine hydrolytic enzyme
-
Development asset linked to Immedica Pharma AB in public FDA and regional records.